CoQ10 and D-ribose in Patients With Diastolic Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Heart Failure, Diastolic
Interventions
DRUG

CoQ10

Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.

DRUG

D-Ribose Oral Powder

Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.

OTHER

Placebo pills

Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.

OTHER

Placebo powder

Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Kansas Medical Center

OTHER

NCT03133793 - CoQ10 and D-ribose in Patients With Diastolic Heart Failure | Biotech Hunter | Biotech Hunter